• Unleashing the Potential of Clinico-Genomic Information: ASCO 2017

    Precision oncology requires a robust understanding of how genomic information relates to clinical outcomes and treatment response. To make this connection, we need to integrate multiple sources of data into single databases that have the power to inform new clinical insights. This has historically been difficult …

    Continue Reading

  • At ASCO 2017, Foundation Medicine is presenting new comprehensive genomic profiling data spanning 15 different tumor types. Learn more about the insights FoundationOne® can provide for both targeted therapies and immunotherapies across a range of different cancers. Learn more about our posters and presentations at …

    Continue Reading

  • This week was the American Association for Cancer Research (AACR) annual meeting in Washington, DC. As we followed the event, we identified the 140-character anecdotes and quotes that shine a light on emerging trends in cancer research. Cancer immunotherapy continues to be a hot topic. While the treatment landscape …

    Continue Reading

  • Diving Deeper Into Cancer Immunotherapy Biomarkers

    Cancer immunotherapy is transforming the treatment landscape for many types of cancer, but identifying those people most likely to benefit from these new treatments is one of the biggest hurdles facing the field. Personalized targeted therapies have traditionally been prescribed based on the presence of single …

    Continue Reading

  • Completing the Puzzle for Colorectal Cancer

    Each person and each cancer is unique, and the goal of precision medicine is to uncover this individuality. For colorectal cancer (CRC), we have discovered a few important pieces of the puzzle, but the entire picture is incomplete. There is an urgent need to discover more specific predictive markers of CRC that can …

    Continue Reading

  • A child getting diagnosed with cancer is devastating and can often be compounded by not knowing how to help, or what to do next. Many pediatric cancers are still not well understood, and it remains the leading cause of death by disease among children in the United States.1 Fortunately, advances in research have …

    Continue Reading

  • Shaping the Future of Liquid Biopsies

    At Foundation Medicine, we firmly believe that precision medicine is the future of cancer care. And if we want to make this future a reality, we need collaboration. Collaboration across multiple partners is essential to realizing the full potential of innovative new technologies that may change the way we identify and …

    Continue Reading

  • The passage of the 21st Century Cures Act on December 7th was a milestone for America’s Precision Medicine initiative. The landmark bill includes $4.8 billion over the coming years for Vice President Biden’s Moonshot Program and, specifically, to advance programs at NIH, NCI and FDA. Further advancing the precision …

    Continue Reading

  • Today, Foundation Medicine introduced FoundationFocus™ CDxBRCA, our first product to be approved by the U.S. Food and Drug Administration (FDA). This companion diagnostic is intended to aid in identifying women with ovarian cancer for whom treatment with Rubraca™ (rucaparib) tablets, a therapy developed by Clovis …

    Continue Reading

  • One in eight women in the US will develop breast cancer in their lifetime.1 Many of these women, however, will ultimately add “survivor” to their diagnosis thanks to today’s treatment options. Breast cancer survival has tripled in the last 60 years2, demonstrating just how far we’ve come in fighting a disease that …

    Continue Reading